Phase Ⅱ Study of FOLFIRI as Second-Line Chemotherapy for Metastatic Esophageal Carcinoma

NCT02023593 Phase 2 COMPLETED

This phase Ⅱ study was designed to evaluate the efficacy and safety of FOLFIRI as second-line treatment for metastatic esophageal carcinoma.

Details

Lead sponsor	Yuhong Li
Phase	Phase 2
Status	COMPLETED
Enrolment	35
Start date	2012-03
Completion	2022-12

Conditions

• Advanced Esophageal Carcinoma

Interventions

• FOLFIRI

Primary outcomes

• Disease control rate — Up to 24 weeks

Countries

China